Opioid Induced Constipation (OIC) Drugs Market to Reach USD 1.79 billion, Globally, by 2031 at 4.9% CAGR: Allied Market Research

Rise in demand for novel drugs for management of opioid induced constipation (OIC) disorder, rise in adoption of methylnaltrexone (parenteral – subcutaneous) for opioid induced constipation (OIC) treatment, and increase in awareness toward use of mu-opioid receptor antagonists and chloride channel type-2 activator drive the global opioid induced constipation (OIC) drugs market.

PORTLAND, Ore., Feb. 24, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Opioid Induced Constipation (OIC) Drugs Market by Drug Type (Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, Others), by Prescription Type (Over The Counter Drugs, Prescribed Drugs), by Distribution Channel (Hospital Pharmacies, Online Providers, Drug Store and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global opioid induced constipation (OIC) drugs industry generated $1.10 billion in 2021, and is estimated to reach $1.79 billion by 2031 witnessing a CAGR of 4.9% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.

Download Free Sample of the Report- https://www.alliedmarketresearch.com/request-sample/13745 

Drivers, Restraints, and Opportunities:  

Rise in demand for novel drugs for management of opioid induced constipation (OIC) disorder, rise in adoption of methylnaltrexone (parenteral – subcutaneous) for opioid induced constipation (OIC) treatment, and increase in awareness towards the use of mu-opioid receptor antagonists and chloride channel type-2 activator drive the global opioid induced constipation (OIC) drugs market. However, side effects of using opioid induced constipation (OIC) drugs, high costs of novel pharmaceuticals, and unfavorable reimbursement policies restrict the market growth. On the other hand, rising R&D activities, surge in regulatory approvals, higher spending for opioid induced constipation (OIC) research, and increase in demand for novel therapeutics for treating opioid induced constipation (OIC) will present new growth opportunities for the global meniscus repair system market in the coming years.   

Impact of COVID-19 on Opioid Induced Constipation (OIC) Drugs Market:  

• The COIVD-19 pandemic positively impacted the growth of the global opioid induced constipation drugs market, owing to rise in the number of patients suffering from chronic pain disorders.
• Opioid misuse increased during the pandemic as people experienced worsened mental health, increased social isolation, increased job losses, and decreased access to treatment, all of which, contributed to the growth of the opioid induced constipation (OIC) drugs market.

Procure Complete Report (359 Pages PDF with Insights, Charts, Tables, and Figures)
https://tinyurl.com/nbhatu54 

The Mu-opioid receptor antagonists' segment to dominate the market during the forecast period:

In terms of drug type, the Mu-opioid receptor antagonists segment contributed to the largest share of more than half of the global opioid induced constipation (OIC) drugs market in 2021, and is expected to maintain progressive growth during the forecast period. The same segment is projected to witness highest CAGR of 5.5% from 2022 to 2031, owing to rise in the number of product launches by the key players for treating opioid induced constipation (OIC) and the rise in research activities for evaluating safety and efficacy of these agents.

The prescribed drugs segment to rule the roost:   

On the basis of prescription type, the prescribed drugs segment contributed to the largest share of more than four-fifths of the global opioid induced constipation (OIC) drugs market revenue, and is expected to retain its dominance by 2031. This is due to the availability of major drugs and rise in number of manufacturing of these formulations by the key players. The over-the-counter drugs segment would portray the fastest CAGR of 6.3% during the forecast period. This is due to rise in adoption of these drugs along with prescribed drugs for opioid induced constipation (OIC) management.

 The drug store and retail pharmacies to dominate in terms of revenue during the forecast period:  

Based on distribution channel, the drug store and retail pharmacies garnered the highest share in 2021, holding more than half of the global opioid induced constipation (OIC) drugs market revenue, and is expected to retain its dominance by 2031. This is due to increase in preference of the people toward retail pharmacies, as retail pharmacies guide patients regarding medications and usage during treatment period. However, the online providers segment is projected to witness highest CAGR of 9.3%, owing to rise in popularity of online pharmacy and number of users preferring online pharmacies.

For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/13745 

North America region garnered the major share in 2021:

By region, North America accounted for the highest share in 2021, holding nearly two-fifths of the global opioid induced constipation (OIC) drugs market revenue, and is projected to rule the roost by 2031. This is owing to the rise in prevalence of opioid induced constipation (OIC) cases, prevalence of advanced healthcare infrastructure and increase in number of key players offering novel therapeutics. The Asia-Pacific region, simultaneously, would portray the fastest CAGR of 6.5% during the forecast period. This is due to increasing number of cancer cases resulting in rise in use of opioids, increase in awareness campaign and rise in investments for development of effective drugs for treating opioid induced constipation (OIC).

Leading Market Players:   

• Takeda Pharmaceutical Company Limited
• Mallinckrodt PLC
• Cosmo Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Novartis AG
• Shionogi & Co. Ltd.
• Bausch Health Companies Inc.
• AstraZeneca plc
• Merck & Co. Inc.

Similar Research Reports for Information, Communication and Technology:

U.S. Patient Monitoring Systems Market - Opportunity Analysis and Industry Forecast, 2021–2030

U.S. Intraoperative Neuromonitoring Market - Opportunity Analysis and Industry Forecast, 2021–2030

Allergy Treatment Market - Global Opportunity Analysis and Industry Forecast, 2021–2030

Immunoglobulin Market - Global Opportunity Analysis and Industry Forecast, 2021–2030

Biopsy Devices Market - Global Opportunity Analysis and Industry Forecast, 2021–2030

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model):

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285 UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com 
Web: https://www.alliedmarketresearch.com

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg